• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxter hits 52-week high on earnings beat

Baxter hits 52-week high on earnings beat

July 18, 2013 By Brad Perriello

Baxter hits 52-week high on earnings beat

Baxter (NYSE:BAX) shares spiked to a 52-week high this morning after the healthcare giant reported Wall Street-beating 2nd-quarter adjusted earnings per share, despite a sales growth miss and sliding profits.

The Deerfield, Ill.-based company reported profits of $590 million, or $1.07 per share, on sales of $3.67 billion for the 3 months ended June 30.

That represents sales growth of 2.7%, lower than Wall Street’s $3.71 billion sales forecast, and a bottom-line slide of 10.7%.

But adjusted for 1-time items, earnings per share were $1.16, ahead of The Street’s expectations by 3¢. That, and a boost to the lower end of Baxter’s full-year earnings guidance, sent shares up today – despite a postponed closing date for its blockbuster buyout of dialysis company Gambro, now slated to close during the 3rd quarter.

"Baxter’s financial results reflect the benefits of our diversified healthcare model," chairman & CEO Robert Parkinson Jr. said in prepared remarks. "We continue to advance care across our key franchises in both developed and emerging markets, while focusing on innovation and R&D programs that will fuel future growth and enhance value for shareholders."

Baxter confirmed its outlook for the rest of the year, saying it still expects sales growth of 8%-9% including the Gambro deal or about 4% excluding that impact. Earnings per share are forecast to be between $4.62 and $4.70 per share, up 2¢ on the lower end from its prior guidance.

Third-quarter sales growth is expected to reach 6% excluding Gambro and 10%-13% including sales from the Swedish company, with EPS slated to reach $1.18-$1.21 per share, according to a press release.

BAX shares reached a high today of $74.14 before subsiding to $73.68 apiece as of about 11 a.m.

Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, News Well Tagged With: 2013, Baxter, Dialysis, Q2

More recent news

  • Philips prices $1.1B offering to pay off debt, finance green projects
  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy